US 20200087414A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2020/0087414 A1**

Spreter Von Kreudenstein et al. (43) **Pub. Date: Mar. 19, 2020**

(54) **STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE FC DOMAIN**

(71) Applicant: **Zymeworks Inc.**, Vancouver (CA)

(72) Inventors: **Thomas Spreter Von Kreudenstein**, Vancouver (CA); **Surjit Bhimarao Dixit**, Richmond (CA); **Eric Escobar-Cabrera**, Burnaby (CA); **Paula Irene Lario**, Vancouver (CA); **David Kai Yuen Poon**, Richmond (CA)

(21) Appl. No.: **16/568,611**

(22) Filed: **Sep. 12, 2019**

Related U.S. Application Data

(62) Division of application No. 15/411,799, filed on Jan. 20, 2017, now Pat. No. 10,457,742, which is a division of application No. 13/668,098, filed on Nov. 2, 2012, now Pat. No. 9,574,010.

(60) Provisional application No. 61/645,547, filed on May 10, 2012, provisional application No. 61/557,262, filed on Nov. 8, 2011, provisional application No. 61/556,090, filed on Nov. 4, 2011.

Publication Classification

(51) **Int. Cl.**

C07K 16/32	(2006.01)
C07K 16/28	(2006.01)
C07K 16/46	(2006.01)
G16B 5/00	(2006.01)

(52) **U.S. Cl.**

CPC ***C07K 16/32*** (2013.01); ***C07K 16/2887*** (2013.01); ***C07K 16/46*** (2013.01); ***C07K 16/468*** (2013.01); *C07K 2317/524* (2013.01); *C07K 2317/52* (2013.01); *C07K 2317/94* (2013.01); *C07K 2317/526* (2013.01); ***G16B 5/00*** (2019.02)

(57) **ABSTRACT**

The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.

Specification includes a Sequence Listing.